Legend Biotech(US:LEGN) Globenewswire·2025-11-27 14:00Core Insights - Legend Biotech has been awarded the Foreign Investor of the Year at the 2025 Flanders International Business Awards, recognizing its significant contributions to the region's biotech sector [1][2] - The company has made a €165 million joint investment with Johnson & Johnson to expand its manufacturing facility in Ghent, enhancing its position as a major CAR-T manufacturing center in Europe [3][4] Company Growth and Operations - Since starting operations in Ghent in 2022, Legend Biotech's workforce has grown from 2 to over 1,000 employees, representing 66 nationalities, with plans for further hiring in the coming years [4] - The Ghent facility, along with the nearby Obelisc site, serves as the European hub for clinical and commercial supply of cell therapies across the EMEA region [3] Strategic Partnerships and Ecosystem - Legend Biotech's growth is closely linked to the strength of the Flemish biotech ecosystem, supported by partnerships with Flanders Investment & Trade (FIT) and collaborations with research institutions like VIB and Ghent University [5] - The company aims to leverage its leadership in CAR-T cell therapy to maximize patient access and drive future innovations in cell therapy modalities [6]